BAIT
TP53
BCC7, LFS1, P53, TRP53
tumor protein p53
GO Process (61)
GO Function (25)
GO Component (14)
Gene Ontology Biological Process
- DNA damage response, signal transduction by p53 class mediator [IDA, IMP]
- DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [TAS]
- DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator [IMP]
- DNA strand renaturation [IDA]
- ER overload response [IDA]
- Notch signaling pathway [TAS]
- Ras protein signal transduction [IEP]
- apoptotic process [TAS]
- base-excision repair [TAS]
- blood coagulation [TAS]
- cell aging [IMP]
- cell cycle arrest [IDA, IMP]
- cell differentiation [TAS]
- cell proliferation [TAS]
- cellular protein localization [IDA]
- cellular response to DNA damage stimulus [IDA]
- cellular response to UV [IBA]
- cellular response to drug [IEP]
- cellular response to glucose starvation [IDA]
- cellular response to hypoxia [IEP]
- cellular response to ionizing radiation [IMP]
- chromatin assembly [IDA]
- determination of adult lifespan [ISS]
- intrinsic apoptotic signaling pathway [TAS]
- intrinsic apoptotic signaling pathway by p53 class mediator [IMP]
- intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [IDA]
- mitotic G1 DNA damage checkpoint [IMP]
- multicellular organismal development [IMP]
- negative regulation of apoptotic process [IDA]
- negative regulation of cell growth [IMP]
- negative regulation of cell proliferation [ISS]
- negative regulation of fibroblast proliferation [IMP]
- negative regulation of helicase activity [TAS]
- negative regulation of transcription from RNA polymerase II promoter [IBA, IDA, ISS]
- negative regulation of transcription, DNA-templated [ISS]
- nucleotide-excision repair [IMP]
- oligodendrocyte apoptotic process [IDA]
- oxidative stress-induced premature senescence [IMP]
- positive regulation of apoptotic process [IDA]
- positive regulation of cell cycle arrest [IMP]
- positive regulation of histone deacetylation [IBA]
- positive regulation of intrinsic apoptotic signaling pathway [IMP]
- positive regulation of neuron apoptotic process [IBA]
- positive regulation of peptidyl-tyrosine phosphorylation [ISS]
- positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway [TAS]
- positive regulation of protein oligomerization [IDA]
- positive regulation of reactive oxygen species metabolic process [IMP]
- positive regulation of release of cytochrome c from mitochondria [IDA]
- positive regulation of thymocyte apoptotic process [ISS]
- positive regulation of transcription from RNA polymerase II promoter [IDA, IGI, IMP]
- positive regulation of transcription, DNA-templated [IDA, IMP]
- protein complex assembly [IDA]
- protein localization [IDA]
- protein tetramerization [TAS]
- regulation of apoptotic process [IDA]
- regulation of mitochondrial membrane permeability [TAS]
- regulation of transcription, DNA-templated [IDA]
- replicative senescence [IMP]
- response to X-ray [IBA]
- response to antibiotic [IEP]
- response to gamma radiation [IMP]
Gene Ontology Molecular Function- ATP binding [IDA]
- DNA binding [IMP]
- RNA polymerase II transcription factor binding [IPI]
- RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription [IDA]
- chaperone binding [IPI]
- chromatin binding [IDA]
- copper ion binding [IDA]
- damaged DNA binding [IBA]
- enzyme binding [IPI]
- histone acetyltransferase binding [IPI]
- identical protein binding [IPI]
- p53 binding [IBA]
- protease binding [IPI]
- protein N-terminus binding [IPI]
- protein binding [IPI]
- protein heterodimerization activity [IPI]
- protein kinase binding [IPI]
- protein phosphatase 2A binding [IPI]
- protein phosphatase binding [IPI]
- receptor tyrosine kinase binding [IPI]
- sequence-specific DNA binding transcription factor activity [IDA]
- transcription factor binding [IPI]
- transcription regulatory region DNA binding [IDA]
- ubiquitin protein ligase binding [IPI]
- zinc ion binding [TAS]
- ATP binding [IDA]
- DNA binding [IMP]
- RNA polymerase II transcription factor binding [IPI]
- RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription [IDA]
- chaperone binding [IPI]
- chromatin binding [IDA]
- copper ion binding [IDA]
- damaged DNA binding [IBA]
- enzyme binding [IPI]
- histone acetyltransferase binding [IPI]
- identical protein binding [IPI]
- p53 binding [IBA]
- protease binding [IPI]
- protein N-terminus binding [IPI]
- protein binding [IPI]
- protein heterodimerization activity [IPI]
- protein kinase binding [IPI]
- protein phosphatase 2A binding [IPI]
- protein phosphatase binding [IPI]
- receptor tyrosine kinase binding [IPI]
- sequence-specific DNA binding transcription factor activity [IDA]
- transcription factor binding [IPI]
- transcription regulatory region DNA binding [IDA]
- ubiquitin protein ligase binding [IPI]
- zinc ion binding [TAS]
Gene Ontology Cellular Component
Homo sapiens
PREY
NR3C2
MCR, MLR, MR, NR3C2VIT
nuclear receptor subfamily 3, group C, member 2
GO Process (3)
GO Function (1)
GO Component (2)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.
TP53 mutations are common in most human cancers, but few therapeutic options for TP53-mutant tumors exist. To identify potential therapeutic options for cancer patients with TP53 mutations, we profiled 127 FDA-approved chemotherapy drugs against human embryonic stem cells (hESC) in which we engineered TP53 deletion by genome editing. We identified 27 cancer therapeutic drugs for which TP53 mutations conferred resistance; ... [more]
Cancer Res Dec. 01, 2018; 79(9);2392-2403 [Pubmed: 30862715]
Throughput
- Low Throughput
Additional Notes
- CRISPR GI screen
- Cell Line: hESC
- Experimental Setup: Drug Exposure: Cisplatin CHEBI:27899
- GIST: Mono-phenotypic suppressing genetic interaction
- KO of hit genes re-sensitizes TP53 KO cells to cisplatin
- Library: GeckoV2
- Significance Threshold: p<0.01
Curated By
- BioGRID